<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656171</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200090</org_study_id>
    <secondary_id>N° IDRCB: 2019-A03171-56</secondary_id>
    <nct_id>NCT04656171</nct_id>
  </id_info>
  <brief_title>Microcephaly, Fanconi Anemia and Praxial Disorders</brief_title>
  <acronym>MicroFancII</acronym>
  <official_title>Microcephaly, Fanconi Anemia and Praxial Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fanconi Anemia (FA) is mentioned in children with congenital malformations including kidney,&#xD;
      hart and skeletal malformations (absence or abnormal thumb or forearm), and bone marrow&#xD;
      failure or myelodysplasia with a progressive onset in childhood or adulthood. No study has&#xD;
      focused on microcephaly, a reduction in brain volume, which is present in 20% of children,&#xD;
      and its consequences on cognitive and structural level of the brain. Since 2014,&#xD;
      Robert-Debré's team has been interested in this functional cognitive and neuroanatomical&#xD;
      approach trough a National PHRC. Preliminary results carried out on 12 children show that&#xD;
      their intellectual efficiency was in the normal range for age. However, we noticed a&#xD;
      significant difference between abilities in comprehension and verbal reasoning corresponding&#xD;
      to what is expected for age, and the sensorimotor skills or fine motor praxia significantly&#xD;
      reduced. These difficulties, graphically penalizing for these children, are not always&#xD;
      explained by a skeletal malformation of the upper limb, suggesting that musculo-tendinous&#xD;
      anomalies may be associated. The objectives of our project are: 1) to identify upper limb&#xD;
      musculo-tendinous abnormalities and their functional consequences, 2) to determine if these&#xD;
      abnormalities could influence the somatosensory representation of the upper limb at the&#xD;
      cerebral cortical level. This project should help us to better understand the fine motor&#xD;
      disabilities or developmental coordination disorder of these children, which penalize their&#xD;
      learning, and provide them with adapted solutions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our hypothesis is that children with FA present a developmental dyspraxia. This condition is&#xD;
      very penalizing for children especially regarding graphic tasks, handwriting, whether or not&#xD;
      they have skeletal malformations of the upper limbs. Consequences are fatigue because of&#xD;
      energy expended trying to execute fine motor movements correctly.&#xD;
&#xD;
      Main objective:&#xD;
&#xD;
      To identify gesture dyspraxia in order to propose a targeted rehabilitation leading to&#xD;
      national recommendations.&#xD;
&#xD;
      Main Evaluation Criteria :&#xD;
&#xD;
        1. measurement of fine motor praxia&#xD;
&#xD;
        2. quantification of dyspraxia&#xD;
&#xD;
      Secondary Objectives :&#xD;
&#xD;
      To identify the musculoskeletal or tendinous anomalies in the upper limbs of AF children and&#xD;
      to assess their functional consequences.&#xD;
&#xD;
      To determine if these upper limbs abnormalities could influence the somatosensory map of this&#xD;
      part of the body in the cerebral cortex.&#xD;
&#xD;
      Secondary Evaluation Criteria :&#xD;
&#xD;
        1. MRI of the hand and forearm, orthopedic examination and functional assessment&#xD;
&#xD;
        2. Previously obtained brain MRI data&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of fine motor praxia</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>Minor patients with Fanconi anemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI of hands and forearm, neuropsychological and neuromotor tests</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minor controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MRI of the hand and forearm, orthopedic evaluation, neuromotor tests of the upper limbs, praxies evaluation, neurocognitive evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI of the hand and forearm,</intervention_name>
    <description>MRI of the hand and forearm,</description>
    <arm_group_label>Minor controls</arm_group_label>
    <arm_group_label>Minor patients with Fanconi anemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with Fanconi Anemia defined according to two of the following diagnostic&#xD;
             criteria already included in the MicroFanc study:&#xD;
&#xD;
               -  Chromosome breakage test after exposure to an alkylating agent (mitomycin) on&#xD;
                  peripheral blood lymphocytes.&#xD;
&#xD;
               -  FancD2 test on lymphocytes or fibroblasts&#xD;
&#xD;
               -  sensitivity of fibroblasts to mitomycin&#xD;
&#xD;
               -  mutation in one of the FANC complementation genes (A, B, C, D1, D2, E, F, G, I,&#xD;
                  J, L, M, N)&#xD;
&#xD;
          2. Non-transplanted patients or patients at a distance from CSH transplant (&gt;3 years)&#xD;
&#xD;
          3. Age ≥5 years of age at inclusion (minimum age of accessibility for neuropsychological&#xD;
             tests and no need for sedation for MRI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects for whom both parents have not agreed to participate in the research, or for whom&#xD;
        MRI is contraindicated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandrine Passemard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandrine Passemard, MD</last_name>
    <phone>+331 40 03 36 91</phone>
    <email>sandrine.passemard@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Robert Drbré Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandrine Passemard, MD</last_name>
      <phone>+331 40 03 36 91</phone>
      <email>sandrine.passemard@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Microcephaly</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

